2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Plasminogen/Plasmin

Plasminogen/Plasmin

Plasmin, the proteolytically active form of plasminogen, utilizes fibrin contained within clots as a substrate for proteolysis, producing soluble products and thus maintaining the patency within the vascular system. The precursor to plasmin, plasminogen, serves as zymogen produced by the liver circulates throughout the endovascular network, and participates in the fibrinolytic pathway, serving as both a catalytic enzyme to initiate the process of fibrinolysis, as well as a substrate, which once cleaved to become plasmin, continues on the process of fibrinolysis at an accelerated rate.

Plasminogen/Plasmin Related Products (8):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-B0236
    6-Aminocaproic acid
    		Inhibitor 99.86%
    6-Aminocaproic acid (EACA), a monoamino carboxylic acid, is a potent and orally active inhibitor of plasmin and plasminogen. 6-Aminocaproic acid is a potent antifibrinolytic agent. 6-Aminocaproic acid prevents clot lysis through the competitive binding of lysine residues on plasminogen, inhibiting plasmin formation and reducing fibrinolysis. 6-Aminocaproic acid can be used for the research of bleeding disorders.
    6-Aminocaproic acid
  • HY-P10005
    D-Val-Gly-Arg-pNA
    D-Val-Gly-Arg-pNA is a chromogenic substrate of TPA (tissue plasminogen activator). D-Val-Gly-Arg-pNA can be used to detect the amidolytic activity of TPA I and TPA II.
    D-Val-Gly-Arg-pNA
  • HY-185319A
    Pexamsiran sodium
    		Inhibitor
    Pexamsiran sodium is a siRNA that inhibits plasminogen synthesis reducer, and can be use for the study of hereditary haemorrhagic telangiectasia.
    Pexamsiran sodium
  • HY-P10005A
    D-Val-Gly-Arg-pNA acetate
    D-Val-Gly-Arg-pNA acetate is a chromogenic substrate of TPA (tissue plasminogen activator). D-Val-Gly-Arg-pNA can be used to detect the amidolytic activity of TPA I and TPA II.
    D-Val-Gly-Arg-pNA acetate
  • HY-182600
    KLK6-IN-1
    		Inhibitor
    KLK6-IN-1 is a reversible small‑molecule inhibitor of KLK6, KLK1, and plasmin. KLK6-IN-1 shows IC50 values of 1.57 μM (KLK6), 5.1 μM (KLK1), 7.4 μM (plasmin), and Ki values of 0.8 μM (KLK6), 2.4 μM (KLK1), 1.3 μM (plasmin). KLK6-IN-1 is highly selective for KLK6 and its proteolytic network. KLK6-IN-1 induces oligodendrocyte differentiation by promoting oligodendrocyte precursor cell maturation. KLK6-IN-1 can be used for the research of multiple sclerosis.
    KLK6-IN-1
  • HY-185319
    Pexamsiran
    		Inhibitor
    Pexamsiran is a siRNA that inhibits plasminogen synthesis, and can be use for the study of hereditary haemorrhagic telangiectasia.
    Pexamsiran
  • HY-182565
    PSI-112
    		Inhibitor
    PSI-112 is a YO-class μPlm inhibitor, with IC50 values of 0.38 μM, 1.48 μM and 0.37 μM against the wild-type, F587A mutant and K607A mutant, respectively. PSI-112 shows low affinity for uPA. PSI-112 can be used in cancer research.
    PSI-112
  • HY-183860
    Pefabloc PL
    		Inhibitor
    Pefabloc PL is a plasmin inhibitor with submicromolar-range inhibitory activity against the trypsin-like serine protease plasmin.
    Pefabloc PL